Sign in to view content

Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study

Mark R. Barakat, MD

Video
Published 2021

Related

It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD
David A. Eichenbaum, MD, FASRS
On Demand Cases, Courses, and Papers
2019
Fluctuations in Central Foveal Thickness and Vision Outcomes With AntiVEGF Therapy for Neovascular Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Updates from the Field
2020
Episode 4: 3-year Results of the TREX-AMD Trial with Dr. Charles Wykoff
Keyvan Koushan, MD, FRCSC
Member Podcasts
2017

Category: AMD-Neovascular

See more